In early afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing the benchmark index is up 0.5% to 6,122.3 points.
Four shares that are climbing more than most today are below, Here’s why they are zooming higher:
The Baby Bunting Group Ltd (ASX: BBN) share price has jumped 8% to $4.06 following the release of its full year results. In FY 2020, the baby products retailer posted an 11.8% increase in total sales to $405.2 million despite the pandemic. And thanks to margin expansion, Baby Bunting delivered a 34.1% increase in pro forma net profit after tax to $19.3 million. Importantly, this was achieved without the company receiving any COVID-19 assistance from the government.
The Evolution Mining Ltd (ASX: EVN) share price is up 5% to $6.02. This appears to have been driven by a rebound in the gold price overnight. It isn’t just Evolution pushing higher today. A number of gold miners are on the rise for the same reason. This has led to the S&P/ASX All Ordinaries Gold index rising 1.5% at the time of writing.
The Mesoblast limited (ASX: MSB) share price has rocketed 38% higher to $4.66. Investors have been fighting to get hold of the biotech company’s shares after a very positive outcome from its meeting with the Oncologic Drugs Advisory Committee (ODAC) overnight. This meeting was to discuss its remestemcel-L product candidate as a treatment for paediatric steroid-resistance acute graft versus host disease (paediatric SR-aGvHD). While the company still needs the U.S. FDA to approve the product, the odds look to be very much in its favour now.
The Xero Limited (ASX: XRO) share price is up 3.5% to $92.50. This appears to be in response to the business and accounting software provider’s annual general meeting update on Thursday. That update revealed that Xero has added 96,000 net subscribers to its platform since the start of April. This lifted its subscribers to a total of 2.38 million at the end of the period.
These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- ASX 200 up 0.3%: NAB Q3 update, Mesoblast rockets, Newcrest guidance disappoints
- Mesoblast share price rockets 57% higher on FDA breakthrough
- Baby Bunting share price in focus after strong FY 2020 profit growth despite the pandemic
- Mesoblast share price on watch after US regulatory approval
- 5 things to watch on the ASX 200 on Friday
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Xero. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Why Baby Bunting, Evolution, Mesoblast, & Xero shares are zooming higher appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2Fia8lX
Leave a Reply